The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
Abstract
Purpose: To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis–free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram. Patients and Methods: Data from 496 patients treated with anthracycline PC at the Institut Gustave Roussy were used to develop and calibrate a nomogram for pCR based on multivariate logistic regression. This nomogram was tested on two independent cohorts of patients treated at the M.D. Anderson Cancer Center. The first cohort (n = 337) received anthracycline; the second cohort (n = 237) received a combination of paclitaxel and anthracycline PC. A separate nomogram to predict DMFS was developed using Cox proportional hazards regression model. Results: The pCR nomogram based on clinical stage, estrogen receptor status, histologic grade, and number of preoperative chemotherapy cycles had good discrimination and calibration in the training and the anthracycline-treated validation sets (concordance indices, 0.77, 0.79). In the paclitaxel plus anthracycline group, when the predicted pCR rate was less than 14%, the observed rate was 7.5%; for a predicted rate of ≥ 38%, the actual rate was 85%. For a predicted rate between 14% to 38%, the observed rates were 50% with weekly and 27% with 3-weekly paclitaxel. This indicates that patients with intermediate chemotherapy sensitivity benefit the most from the optimized schedule of paclitaxel. Patients unlikely to achieve pCR to anthracylines remain at low probability for pCR, even after inclusion of paclitaxel. The nomogram for DMFS had a concordance index of 0.72 in the validation set and outperformed other prediction tools (P = .02). Conclusion: Our nomograms predict pCR accurately and can serve as a basis to integrate future molecular markers into a clinical prediction model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330
Self-citationNeoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Self-citationvan der Hage, J. A., van de Velde, C. J. H., Julien, J.-P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L., & Cooperating Investigators (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4224 · Cited by 1,107
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. E., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,070
Ravdin, P. M., Siminoff, L. A., Davis, G. J., Mercer, M. B., Hewlett, J., Gerson, N., & Parker, H. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.980 · Cited by 996
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., Ah-See, A. K., Eremin, O., Walker, L. G., Sarkar, T. K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1456 · Cited by 782
Two Further Applications of a Model for Binary Regression
Cox, D. R. (1958) · Biometrika · doi:10.2307/2333203 · Cited by 557
Two further applications of a model for binary regression
COX, D. R. (1958) · Biometrika · doi:10.1093/biomet/45.3-4.562 · Cited by 556
Fisher, B., Redmond, C., Fisher, E. R., & Caplan, R. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.7.1076 · Cited by 419
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408974102 · Cited by 413
Self-citationRouzier, R., Extra, J.-M., Klijanienko, J., Falcou, M.-C., Asselain, B. J. R., Vincent‐Salomon, A., Vielh, P. R., & Bourstyn, E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1304 · Cited by 315
Self-citationContesso, G., Mouriesse, H., Friedman, S., Genin, J., Sarrazin, D., & Rouesse, J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1378 · Cited by 261
Rajan, R., Poniecka, A., Smith, T. L., Yang, Y., Frye, D., Pusztai, L., Fiterman, D. J., Gal‐Gombos, E., Whitman, G., Rouzier, R., et al. (2004) · Cancer · doi:10.1002/cncr.20134 · Cited by 162
Self-citationScholl, S., Pierga, J., Asselain, B. J. R., Beuzeboc, P., Dorval, T., García-Giralt, E., Jouve, M., Palangié, T., Remvikos, Y., Durand, J. C., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00454-8 · Cited by 152
Schwartz, G. F., & Hortobágyi, G. N. (2004) · Cancer · doi:10.1002/cncr.20298 · Cited by 142
Nomograms as predictive models
Eastham, J. A., Kattan, M. W., & Scardino, P. T. (2002) · Seminars in Urologic Oncology · doi:10.1053/suro.2002.32936 · Cited by 101
Valero, V., Buzdar, A. U., McNeese, M. D., Singletary, E. S., & Hortobágyi, G. N. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.s.014 · Cited by 51
Self-citationA tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy
Kattan, M. W., Giri, D. D., Panageas, K. S., et al. (2004) · Cancer · doi:10.1002/cncr.20635 · Cited by 49
Pusztai, L., & Gianni, L. (2004) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0025 · Cited by 24
Self-citation
Cited by
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Hess, K. R., Anderson, K., Symmans, W. F., Valero, V., Ibrahim, N., Mejia, J. A., Booser, D., Theriault, R. L., Buzdar, A. U., Dempsey, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6861 · Cited by 721
Self-citation
Metadata
- Authors
- Rouzier, R., Pusztai, L., Delaloge, S., Gonzalez-Angulo, A. M., Andre, F., Hess, K. R., Buzdar, A. U., Garbay, J.-R., Spielmann, M., Mathieu, M.-C., Symmans, W. F., Wagner, P., Atallah, D., Valero, V., Berry, D. A., & Hortobagyi, G. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-20
- Volume
- 23
- Issue
- 33
- Pages
- 8331-8339
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170003495
- Cited by
- 286
- References
- 21
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.